CTRI/2009/091/000723尚未招募1 期
An open label, randomized, three period, single-dose, crossover study to determine the bioavailability of 300 mg aliskiren mini-tablets relative to the 300 mg aliskiren market tablet under fasted condition and to evaluate the effect of food on the pharmacokinetics of 300 mg aliskiren minitablets in healthy subjects
ovartis Healthcare Private Limited0 个研究点目标入组 69 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Healthy male and female subjects ( women of non-child bearing
排除标准
- •Female subjects of child bearing potential. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.
研究者
相似试验
进行中（未招募）
不适用
Study to determine bioavailablity of 300 mg aliskiren mini-tablets vs 300 mg aliskiren market tablet.MedDRA version: 14.1Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersHypertensionEUCTR2012-000855-15-Outside-EU/EEAovartis Pharma Services AG69
Unknown
1 期
A study to evaluate effect of single oral dose of SDN-118 Capsules in healthy adult Human subjectsCTRI/2020/03/024009Sun Pharma Advanced Research Company Limited
进行中（未招募）
1 期
An open label, randomized, three-period, three-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to Valtrex® extemporaneous suspension in normal, healthy subjects under fasting conditions and to investigate the effect of food on the bioavailability of Valacyclovir Oral Suspension.ot applicable (submitted trial is a bioequivalence study in healthy subjects)MedDRA version: 20.0Level: HLGTClassification code: 10047438Term: Viral infectious disorders Class: 10021881CTIS2023-504760-42-00Dermax30
已完成
不适用
An randomly assigned, two-treatment, balanced, single dose study to evaluate the Pharmacokinetics and Pharmacodynamics of Intravenous Injection of REPOITIN and Human Serum Albumin - Free REPOITIN Injection of Serum Institute compared to licensed EPO injection injection in healthy adult subjectsCTRI/2015/11/006383Serum Institute of India Ltd66
已完成
不适用
An randomly assigned, two-treatment, balanced, single dose study to evaluate the Pharmacokinetics and Pharmacodynamics of subcutaneous Injection of REPOITIN and Human Serum Albumin - Free REPOITIN Injection of Serum Institute compared to licensed EPO injection injection in healthy adult subjectsCTRI/2015/04/005670Serum Institute of India Ltd48